Label Changes for:

Lumizyme (alglucosidase alfa)

July 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2012

 

 

ADVERSE REACTIONS

Postmarketing Experience
  • abdominal pain, nephrotic syndrome and proteinuria, as observed events to the package insert
Hide
(web5)